Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - VistaGen Therapeutics, Inc. | vtgn8k_july2021.htm |
Exhibit
16.1
July
21, 2021
Securities
and Exchange Commission
100 F
Street, N.E.
Washington,
DC 20549-7561
Ladies
and Gentlemen:
We have
read VistaGen Therapeutics, Inc.’s statements included under
Item 4.01 of its Form 8-K dated July 21, 2021, and are in
agreement with the statements contained therein concerning our firm
in response to Item 304(a) of Regulation S-K.
Very
truly yours,
/s/ OUM
& Co. LLP